Two major vaccine makers from Hyderabad, Biological E Ltd and Bharat Biotech, together are holding about 250 million doses of COVID-19 vaccines ready to dispatch as and when orders are received.
According to respective company sources, Biological E is holding 200 million doses of its COVID-19 vaccine Corbevax while Bharat Biotech is sitting on a stockpile of 50 million doses of Covaxin, reported Press Trust of India.
Dr Vikram Paradkar, Executive Vice President (Manufacturing), Biological E, said the firm produced about 30 crore doses of Corbevax in total, abiding by the vaccine manufacturing commitment to the Central government.
In March '22, Biological E successfully supplied 10 crore doses to the government.
"Currently, we have approximately 20 crore (200 million) doses that are fully tested and ready for supply, as and when we receive orders. Additionally, we manufactured 20 crore doses equivalent of the antigen which will help us ramp up the manufacturing of the Corbevax finished product quickly," Vikram Paradkar told Press Trust of India.
The vaccine has been developed by Biological E in collaboration with Texas Children's Hospital Center for Vaccine Development (Texas Children's CVD) and Baylor College of Medicine (Baylor) in Houston, Texas, USA.
He further said Biological E can begin with the additional vaccine supplies within eight weeks of future orders and can manufacture and supply approximately 10 crore doses of Corbevax on a monthly basis as per its qualified manufacturing capacity.
Bharat Biotech sources said the vaccine maker has more than 50 million doses of Covaxin readily available in vials, and over 200 million doses as drug substance.
"Additional production capacity is also available to meet product demand," they said adding fresh stocks of the vaccine are available and ready for supplies.
Covaxin, India's indigenous COVID-19 vaccine, was developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV).
Due to lack of product demand, production stoppage of Covaxin was initiated earlier this year and also the 50 million doses in vials are set to expire during early 2023, resulting in losses to the company, sources had earlier said.
(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)
Featured Video Of The Day
Tomatoes Thrown, Protest Outside Allu Arjun's Home Over Stampede Death
Bharat Biotech Unveils Next-Gen Oral Cholera Vaccine To Address Global Health Gaps Bharat Biotech Launches Oral Cholera Vaccine After Successful Phase 3 Trial Bharat Biotech Adds Top Medical Body ICMR As Co-Owner Of Covid Vaccine Patent 3 Khalistani Terrorists, Who Attacked Punjab Cops, Killed In UP Encounter Pics: Rahul Gandhi's Family Lunch At Iconic Delhi Restaurant Bashar Al-Assad's Wife Files For Divorce, Wants To Return To UK: Report "Working Longer Is...": Congress MP On Narayan Murthy's 70-Hour Workweek Bashar Al-Assad's Wife Files For Divorce, Wants To Return To UK: Report Narayana Murthy Says Climate Change May Trigger Mass Migration To Bengaluru Track Latest News Live on NDTV.com and get news updates from India and around the world.